Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: lamivudine

« Back to Dashboard
Lamivudine is the generic ingredient in six branded drugs marketed by Viiv Hlthcare, Glaxosmithkline, Silarx Pharms Inc, Apotex, Apotex Inc, Aurobindo Pharma Ltd, Hetero Labs Ltd V, Lupin Ltd, Mylan Pharms Inc, Merck Sharp Dohme, Strides Arcolab Ltd, and Teva Pharms, and is included in twenty NDAs. There are eight patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has forty patent family members in twenty-eight countries.

There are twenty-four drug master file entries for lamivudine. Eight suppliers are listed for this compound. There are sixty tentative approvals for this compound.

Summary for Generic Name: lamivudine

Tradenames:6
Patents:8
Applicants:12
NDAs:20
Drug Master File Entries: see list24
Suppliers / Packaging: see list19
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Tentative approvals for LAMIVUDINE

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 200MG
<disabled><disabled>TABLET; ORAL150MG; 300MG; 600MG

Clinical Trials for: lamivudine

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load
Status: Active, not recruiting Condition: Hepatitis B, Chronic

Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
Status: Completed Condition: Human Immunodeficiency Virus

Pharmacokinetics of Lamivudine at Two Different Doses
Status: Completed Condition: HIV Infections

Comparison Between Lamivudine and Entecavir Treatment in Patients
Status: Recruiting Condition: Chronic Hepatitis B

Estimate The Effect Of Lersivirine On The Pharmacokinetics Of Abacavir/Lamivudine In Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Lamivudine and Adefovir Dipivoxil Fixed Dose Combination
Status: Completed Condition: Hepatitis B, Chronic

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL205217-001Dec 18, 2014RXNo<disabled><disabled>
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015RXYes7,435,734<disabled><disabled>
Aurobindo Pharma Ltd
LAMIVUDINE
lamivudine
TABLET;ORAL202032-001Nov 17, 2011RXNo<disabled><disabled>
Merck Sharp Dohme
DUTREBIS
lamivudine; raltegravir potassium
TABLET;ORAL206510-001Feb 6, 2015RXYes7,169,780<disabled>YY<disabled>
Hetero Labs Ltd V
LAMIVUDINE
lamivudine
TABLET;ORAL203277-002Jan 6, 2014RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: lamivudine

Country Document Number Publication Date
European Patent Office0517145Dec 09, 1992
South Korea100244008Mar 02, 2000
Australia656379Feb 02, 1995
Slovakia125793Nov 09, 1994
Ireland20020782Apr 02, 2003
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc